Pfizer's PCSK9 meets Phase-II primary endpoint

Share this article:

Pfizer has issued the results of its Phase-II trial for PCSK9 cholesterol lowering treatment bococizumab (RN316). The drugmaker said the study met its primary endpoint across all doses, “showing that bococizumab significantly reduced lipoprotein cholesterol (LDL-C) from baseline compared to placebo in adults with high cholesterol also taking statin therapy."

Patients were either dosed twice monthly, or once monthly. Both groups “were associated with significant placebo-adjusted reductions in LDL-C” by week 12 of therapy, the drugmaker stated.

Pfizer's global medicines development lead, Dr. Steven Romano, said “we are pleased with the outcome of this Phase 2b study and continue to maintain focus on developing our Phase-III program, which includes two CV outcome studies in populations at high risk from cardiovascular events. Recent guidelines emphasize the reduction of CV risk as the primary goal of lipid therapy" for those patients, he added. The drug's Phase-III trial began in October 2013.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.